Skip to main content
. Author manuscript; available in PMC: 2024 Jul 2.
Published in final edited form as: Proteoglycan Res. 2023 Aug 9;1(3):e9. doi: 10.1002/pgr2.9

FIGURE 2.

FIGURE 2

Sulfated heparan compounds inhibit Streptococcus pneumoniae corneal infection. (A) Injured corneas were topically coinfected with 108 cfu of S. pneumoniae TIGR4 and PBS (control) or 200 ng of heparinase I-digested HS (HepI HS), heparinase III-digested HS (HepIII HS), or heparosan (H) and the corneal bacterial burden was measured at 6 h pi (mean ± SE, n = 6–8, *p < 0.05). (B) Injured corneas were topically coinfected with 108 cfu of TIGR4 and HP 4-mer (800 ng), 6-mer (500 ng), 12-mer (400 ng), or 18-mer (200 ng) oligosaccharides and the corneal bacterial burden was assessed at 6 h pi (mean ± SE, n = 4–6, *p < 0.05, **p < 0.01, ***p < 0.001). HP, heparin; HS, heparan sulfate; pi, postinfection.